OSE Immunotherapeutics Announces Issuance of a New Patent in Japan for Tedopi® on Inducing Early T-Lymphocyte Memory Response

World News: . []

NANTES, France, Jan. 14, 2020 (GLOBE NEWSWIRE) -- (ISIN: FR0012127173; Mnémo: OSE) today announced that the Japanese Patent Office has issued a new patent family related to Tedopi, a combination of neoepitopes, protecting the product’s method for inducing early T-lymphocyte memory response for use in the treatment of cancer in HLA-A2 positive patients. This patent provides a protection until 2035.

Tedopi is a combination of 10 neo-epitopes, selected and optimized from five tumor-associated antigens inducing a specific immune response in positive HLA-A2 patients. In association with T helper cells, the memory T lymphocytes recognize specifically at least one of these tumor-associated antigens expressed by the tumor cells and generate a specific cytotoxic response against them.

Due to this specific mechanism of action, activated specific T memory lymphocytes are key cells in cancer treatment and immunosurveillance. 

Tedopi is currently being evaluated in a Phase 3 trial, called , in advanced non-small cell lung cancer (NSCLC) for HLA-A2 positive patients after failure from previous treatment with PD-1/PD-L1 checkpoint inhibitors. Even with recent advances in treatment options, the majority of NSCLC patients still fail to respond to checkpoint inhibitor therapy**, creating a great need for an effective new option for these patients. Results from the first step of this ongoing Phase 3 trial are expected by the end of Q1 2020. Tedopi is also being studied in an ongoing Phase 2 trial in patients with pancreatic cancer.

For more information:

Click and follow us on Twitter and LinkedIn

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 26 April 2019, including the annual financial report for the fiscal year 2018, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

More news and information about OSE Immunotherapeutics

Published By:

Globe Newswire: 07:00 GMT Tuesday 14th January 2020

Published: .

Search for other references to "immunotherapeutics" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2020. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us